Skip to content Skip to footer
Subscribe Now
PharmaShots Interview Novartis’ Todd Fox Shares Insight on the US FDA's Approval of Cosentyx for Enthesitis-Related Arthritis and Psoriatic Arthritis
VIEWPOINTS
PharmaShots Interview: Novartis’ Todd Fox Shares Insight on the US FDA’s Approval of Cosentyx for Enthesitis-Related Arthritis and Psoriatic Arthritis
In an interview with PharmaShots, Todd Fox, Global Medical Franchise Head, Immunology Hepatology and Dermatology at Novartis shares his views on Cosentyx in P-III (JUNIPERA) study for the treatment of enthesitis-related arthritis and psoriatic arthritisShots:The approval is based on the P-III (JUNIPERA) study to evaluate Cosentyx (75/150mg) vs PBO in 86 children & adolescents aged 2 to 18yrs. with ERA…
February 22, 20220Comments
Exclusive_Nikhil Lalwani_2022
EXCLUSIVE
Exclusive Interview with PharmaShots: Nikhil Lalwani of ANI Pharmaceuticals Shares Insight on Purified Cortrophin Gel
In an interview with PharmaShots, Nikhil Lalwani, President, and CEO at ANI Pharmaceuticals shared his views on the launch of Purified Cortrophin Gel for the treatment of multiple chronic autoimmune disordersShots:The company launches Purified Cortrophin Gel for the treatment of chronic autoimmune disorders, including acute exacerbations of MS, RA, and excess urinary protein due to nephrotic syndromeCortrophin Gel is an…
February 21, 20220Comments
PharmaShots Interview PolyPid’s Dikla Czaczkes Akselbrad Shares Insights on the P-III (SHIELD I) Trial of D-PLEX100
VIEWPOINTS
PharmaShots Interview: PolyPid’s Dikla Czaczkes Akselbrad Shares Insights on the P-III (SHIELD I) Trial of D-PLEX100
In an interview with PharmaShots, Dikla Czaczkes Akselbrad, Executive Vice President, Chief Financial Officer at PolyPid shares her views on Q3’21 financial results & P-III (SHIELD I) trial of D-PLEX100 in patients with incisional SSIs in post-abdominal surgeryShots:The P-III (SHIELD I) trial evaluates the efficacy and safety of D-PLEX100 in ~500 patients with incisional SSIs in post-abdominal surgery. The trial continues to enroll…
February 16, 20220Comments
VIEWPOINTS
PharmaShots Interview: 180 Life Sciences’ Dr. Jim Woody Shares Insight on Repurposing Anti-TNF to Meet Unmet Needs in Pain and Inflammation
In an interview with PharmaShots, Dr. Jim Woody, MD, Ph.D., Chief Executive Officer at 180 Life Sciences shared his insights on the Phase 2b study of anti-TNF for the treatment of the early Dupuytren's disease.Shots:180 Life Sciences used anti-TNF to treat early Dupuytren’s disease and the Phase 2b study is complete.Additional programs using anti-TNF soon to…
February 15, 20220Comments
Exclusive_John Meduri_2022
EXCLUSIVE
Exclusive Interview with PharmaShots: John Meduri of Accelerate Diagnostics Shares Insight on Antimicrobial Resistance or AMR
In an interview with PharmaShots, John Meduri, Chief Strategy Officer at Accelerate Diagnostics shared his views on antimicrobial resistance and discuss the epidemiology of AMR cases in the US and worldwide. He also shared his views on Accelerate Pheno system and PhenoTest BC kit.Shots:Antibiotic resistance occurs when bacteria develop the ability to defeat…
February 14, 20220Comments
Life Sciences Deals Top 20 2021
TOP 20
Top 20 Life Sciences Deals of 2021 by Total Deal Value
Shots:The life science industry saw high deal activity in 2021 staying in the range of an even busier 2020.Fourth-quarter 2021 set the tone with Recursion’s development and commercialization deal with Roche and Genentech for a total value of $12.7B, followed by Poseida Therapeutics’ development and commercialization deal with Takeda for $3.73B.This article is based on the 2021…
February 10, 20220Comments
PharmaShots Interview Myriad Genetics’ Todd Cohen Shares Insights on the Trends in Prostate Cancer and Precision Medicine
VIEWPOINTS
PharmaShots Interview: Myriad Genetics’ Todd Cohen Shares Insights on the Trends in Prostate Cancer and Precision Medicine
In an interview with PharmaShots, Todd Cohen, MD, Vice President of Medical Affairs/Medical Director of Urology at Myriad Genetics shares his views on the precision medicine and prognostic tests for Prostate CancerShots:The company reported the importance of precision medicine and prognostic tests that can help to determine cancer & enables personalized treatment paths. The company highlights the ability of genetic…
February 9, 20220Comments
Viewpoints_Philip M. Brown
VIEWPOINTS
PharmaShots Interview: Dermavant’s Philip M. Brown Shares Insights on the Clinical Data of Tapinarof Published in NEJM
In an interview with PharmaShots, Philip M. Brown, MD, JD, Chief Medical Officer at Dermavant shares his views on the P-III (PSOARING 1 & 2) trials of tapinarof for the treatment of Plaque PsoriasisShots:The P-III (PSOARING 1 & 2) trials evaluate the efficacy and safety of tapinarof (1%, qd) vs vehicle-controlled cream in a ratio (2:1) in 1025 patients aged…
February 8, 20220Comments